Bayer’s Eylea Sees Good Start In Japan Thanks To Partnering
This article was originally published in PharmAsia News
Executive Summary
Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.
You may also be interested in...
Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.
Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
Pipeline Watch: Phase III Readouts For Dry Eye, Menopause
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Need a specific report? 1000+ reports available
Buy Reports